Journal Basic Info

  • Impact Factor: 2.709**
  • H-Index: 11 
  • ISSN: 2474-1663
  • DOI: 10.25107/2474-1663
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Neoadjuvant Therapy
  •  Kidney Cancer
  •  Chemoprevention
  •  Radiological Techniques and Scans
  •  Sarcomas
  •  Carcinomas
  •  Radiation Oncology
  •  Urological Cancers


Citation: Clin Oncol. 2018;3(1):1492.DOI: 10.25107/2474-1663.1492

Nodal Peripheral T-cell Lymphomas: Progress in the Treatment

Maria K. Angelopoulou, John Asimakopoulos, Iliana Konstandinou, Theodoros P. Vassilakopoulos, Gerasimos Tsourouflis, Marina P Siakantaris and Kostas Konstantopoulos

Department of Hematology, Athens University Medical School, Greece

*Correspondance to: Maria K. Angelopoulou 

 PDF  Full Text Review Article | Open Access


Peripheral T-cell Lymphomas (PTCL) arise from mature T-cells and they represent an extremely heterogeneous group. They are sub-classified into three major groups based on clinical presentation and localization, namely thenodal, extra nodal and leukemic PTCL. This review focuses on nodal PTCL which are the most frequently encountered entities. Nodal PTCL are divided into three basic categories: systemic anaplastic large-cell lymphoma (ALK+ sALCL and ALK- sALCL), Angioimmunoblastic T-Cell Lymphoma (AITL) and peripheral T-cell lymphoma not otherwise specified (PTCL-NOS).Nodal PTCL have a poor outcome with a 5-year Progression Free Survival (PFS) and Overall Survival (OS) of 25% to 38% and 30% to 45%, respectively. There is no standard treatment for these malignancies, so that the therapeutic strategy used in aggressive B-lymphomas has been adopted. Anthracycline-containing chemotherapy like CHOP is more often applied in the front line.The addition of etoposide to classic CHOP seems to favour patients under 60 years and especially those with ALK+ sALCL. Autologous Transplantation (ASCT) is used either as consolidation therapy following first complete remission or at relapse after salvage chemotherapy. Allogeneic transplantation (allo-SCT) is an option usually after ASCT failure. Newer agents are investigated mainly in the Relapsed/ Refractory (R/R) setting, while, the most activeones are being tested in front-line treatment, usually in combination with chemotherapy. These include nucleoside analogues (the main agent of this group is gemcitabine), antifolates such as plaratrexate and inhibitors of histone deacetylase likeromidepsin and belinostat. Among the newer agents, BrentuximabVedotin (BV)- an anti-CD30 antibody drug conjugate - has impressive activity in sALCLand has changed the dismal prognosis of R/R sALCL, especially ALK-. Lately, progress has been made in the understanding of the biology of PTCL. Therefore, new biological subsets have been identified which are characterized by activation of intracellular pathways offering new potential therapeutic targets. However, despite the plethora of new therapeutic agents, the natural history and prognosis of PTCL have not substantially improved yet. Hopefully, the understanding of the biological heterogeneity of these malignancies may enable a successful treatment approach. Multiple and overlapping pathways are possibly involved in the pathogenesis of these entities; clinical research should investigate the combination of chemotherapy with biological agents.


Cite the Article:

Angelopoulou MK, Asimakopoulos J, Konstandinou I, Vassilakopoulos TP, Tsourouflis G, Siakantaris MP, et al. Nodal Peripheral T-cell Lymphomas: Progress in the Treatment. Clin Oncol. 2018; 3: 1492.

Search Our Journal

Journal Indexed In

Articles in PubMed

LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
 PubMed  PMC  PDF  Full Text
NMR Metabolomics in Ionizing Radiation
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Pregnancy Associated Breast Cancer Prognosis and Outcome, Qatar Experience
 Abstract  PDF  Full Text
Ezrin Intracellular Cytoskeleton Marker is Over Expressed in Pancreatic Ductal Adenocarcinoma: A Prospective Cohort Study
 Abstract  PDF  Full Text
View More...